Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease (COPD-PH)

January 13, 2026 updated by: Medical University of Graz

Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease - a Retrospective Multi-center Data Analysis

Registry of COPD (Chronic Obstructive Pulmonary Disease) patients who underwent right heart catheterization (RHC) and full clinical evaluation for pulmonary hypertension

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Graz, Austria
        • Recruiting
        • Medical University of Graz
        • Contact:
        • Principal Investigator:
          • Gabor Kovacs, MD
  • Switzerland
      • Zurich, Switzerland
        • Recruiting
        • University of Zurich
        • Principal Investigator:
          • Silvia Ulrich, MD
        • Contact:
  • United Kingdom
      • Sheffield, United Kingdom
        • Recruiting
        • University of Sheffield
        • Contact:
        • Principal Investigator:
          • Robin Condliffe, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

COPD patients who underwent RHC

Description

Inclusion Criteria:

  • clinical diagnosis of COPD
  • right heart catheterization including mPAP (Mean Pulmonary Artery Pressure), PVR (Pulmonary Vascular Resistance), PAWP (Pulmonary Artery Wedge Pressure), CO (cardiac output)
  • age >= 18 years

Exclusion Criteria:

  • pediatric patients
  • no COPD or no RHC

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severe Pulmonary Hypertension (PH)
Time Frame: at inclusion
pulmonary vascular resistance > 5 WU (Wood Units)
at inclusion
all-cause mortality
Time Frame: Until 2026
all-cause mortality
Until 2026

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Graz

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2025

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

July 30, 2025

First Submitted That Met QC Criteria

July 30, 2025

First Posted (Actual)

August 5, 2025

Study Record Updates

Last Update Posted (Estimated)

January 14, 2026

Last Update Submitted That Met QC Criteria

January 13, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 35-272ex22/23

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Hypertension

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe